

Antibiotic Drug Discovery

New Targets and Molecular Entities

Drug Discovery Series

Editor-in-chief

David Thurston, *King's College, UK*

Series editors:

David Fox, *Vulpine Science and Learning, UK*

Ana Martinez, *Centro de Investigaciones Biologicas-CSIC, Spain*

David Rotella, *Montclair State University, USA*

Sarah Skerratt, *Convergence, UK*

Editorial advisor:

Hong Shen, *Roche Innovation Center Shanghai, China*

Titles in the Series:

- 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups
- 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1
- 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2
- 4: Accounts in Drug Discovery
- 5: New Frontiers in Chemical Biology
- 6: Animal Models for Neurodegenerative Disease
- 7: Neurodegeneration
- 8: G Protein-Coupled Receptors
- 9: Pharmaceutical Process Development
- 10: Extracellular and Intracellular Signaling
- 11: New Synthetic Technologies in Medicinal Chemistry
- 12: New Horizons in Predictive Toxicology
- 13: Drug Design Strategies: Quantitative Approaches
- 14: Neglected Diseases and Drug Discovery
- 15: Biomedical Imaging
- 16: Pharmaceutical Salts and Cocrystals
- 17: Polyamine Drug Discovery
- 18: Proteinases as Drug Targets
- 19: Kinase Drug Discovery
- 20: Drug Design Strategies: Computational Techniques and Applications
- 21: Designing Multi-Target Drugs
- 22: Nanostructured Biomaterials for Overcoming Biological Barriers
- 23: Physico-Chemical and Computational Approaches to Drug Discovery
- 24: Biomarkers for Traumatic Brain Injury
- 25: Drug Discovery from Natural Products
- 26: Anti-Inflammatory Drug Discovery
- 27: New Therapeutic Strategies for Type 2 Diabetes: Small Molecules
- 28: Drug Discovery for Psychiatric Disorders
- 29: Organic Chemistry of Drug Degradation
- 30: Computational Approaches to Nuclear Receptors

- 31: Traditional Chinese Medicine
- 32: Successful Strategies for the Discovery of Antiviral Drugs
- 33: Comprehensive Biomarker Discovery and Validation for Clinical Application
- 34: Emerging Drugs and Targets for Parkinson's Disease
- 35: Pain Therapeutics; Current and Future Treatment Paradigms
- 36: Biotherapeutics: Recent Developments using Chemical and Molecular Biology
- 37: Inhibitors of Molecular Chaperones as Therapeutic Agents
- 38: Orphan Drugs and Rare Diseases
- 39: Ion Channel Drug Discovery
- 40: Macrocycles in Drug Discovery
- 41: Human-based Systems for Translational Research
- 42: Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics
- 43: Carbohydrates in Drug Design and Discovery
- 44: Drug Discovery for Schizophrenia
- 45: Cardiovascular and Metabolic Disease: Scientific Discoveries and New Therapies
- 46: Green Chemistry Strategies for Drug Discovery
- 47: Fragment-Based Drug Discovery
- 48: Epigenetics for Drug Discovery
- 49: New Horizons in Predictive Drug Metabolism and Pharmacokinetics
- 50: Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation
- 51: Nanomedicines: Design, Delivery and Detection
- 52: Synthetic Methods in Drug Discovery: Volume 1
- 53: Synthetic Methods in Drug Discovery: Volume 2
- 54: Drug Transporters: Role and Importance in ADME and Drug Development
- 55: Drug Transporters: Recent Advances and Emerging Technologies
- 56: Allosterism in Drug Discovery
- 57: Anti-aging Drugs: From Basic Research to Clinical Practice
- 58: Antibiotic Drug Discovery: New Targets and Molecular Entities

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House,
Science Park, Milton Road, Cambridge, CB4 0WF, UK
Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,
Email: booksales@rsc.org
Visit our website at www.rsc.org/books

Antibiotic Drug Discovery

New Targets and Molecular Entities

Edited by

Steven M. Firestine

Wayne State University, Detroit, USA

Email: sfirestine@wayne.edu

and

Troy Lister

Spero Therapeutics, Cambridge, USA

Email: troy@sperotherapeutics.com



Drug Discovery Series No. 58

Print ISBN: 978-1-78262-424-0

PDF eISBN: 978-1-78262-987-0

EPUB eISBN: 978-1-78801-149-5

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2017

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

Whilst this material has been produced with all due care, The Royal Society of Chemistry cannot be held responsible or liable for its accuracy and completeness, nor for any consequences arising from any errors or the use of the information contained in this publication. The publication of advertisements does not constitute any endorsement by The Royal Society of Chemistry or Authors of any products advertised. The views and opinions advanced by contributors do not necessarily reflect those of The Royal Society of Chemistry which shall not be liable for any resulting loss or damage arising as a result of reliance upon this material.

The Royal Society of Chemistry is a charity, registered in England and Wales, Number 207890, and a company incorporated in England by Royal Charter (Registered No. RC000524), registered office: Burlington House, Piccadilly, London W1J 0BA, UK, Telephone: +44 (0) 207 4378 6556.

For further information see our web site at www.rsc.org

Printed in the United Kingdom by CPI Group (UK) Ltd, Croydon, CR0 4YY, UK

Preface

The introduction of penicillin 75 years ago ushered in, arguably, the greatest advancement in the history of medicine. Its discovery by Fleming and subsequent demonstration of efficacy and mass production by Florey and others contributed significantly to the Allied war effort saving many thousands of lives. The broad application of penicillin during and after World War II demonstrated the great benefit antibiotics provided the medical community in treating surgical-, wound-, skin- and systemic-based infections. The continued discovery and development of antibiotics throughout the 1950's to the 1970's bolstered the number of new therapeutics available to doctors to treat a wide variety of infections. This golden age of antibiotic discovery resulted in generations of humans that never feared acquiring a life-threatening infection. Indeed, antibiotics performed so well through the later part of the 20th century that many people in the industrialized world have forgotten the significant threat that bacterial infections pose to humans. Infectious disease was the second leading cause of death in the United States prior to World War II and remains the leading cause of death worldwide today (primarily driven by neglected tropical infections in the developing world). Thus, despite the tremendous discovery and innovation in the field of infectious disease medicine over the past seven decades, bacterial infections remain a significant worldwide scourge.

Even with the successes achieved from 1950–2000, the turn of the century has seen a significant increase in antibiotic-resistance and a heightened awareness of the emergent threat. Antibiotic resistance has always existed. Indeed, resistance to penicillin was detected only a few years after its introduction into clinical practice. Yet, this problem is now more severe because of the rise of resistance in pathogenic bacteria and because we are beginning to identify bacteria that are resistant to all currently available classes of

antibiotics. This is particularly troubling because historically, resistance was dealt with by simply switching to another antibiotic. The rise of multi-drug-resistant organisms renders this method of treatment challenging and risky for clinicians.

How did we get here? There are a multitude of factors that played a role. The previously mentioned success in identifying new antibiotics cultivated hubris in thinking that the infectious microbial world had or could be conquered. Economics also played a major role. Many large pharmaceutical companies exited infectious disease drug discovery as research and development became increasingly expensive, protracted clinical trials slowed development and the expectation by payers and the public that antibiotics should be low cost hindered a return on investment. The scientific community too grew weary of a growing list of failed drug discovery and development campaigns, the lack of novel targets and the feeling that nothing innovative remained to be uncovered in antibiotic drug discovery. Lastly, governments worldwide were slow in appreciating the threat posed by antimicrobial resistance and historically have done little to facilitate the advancement of therapeutics. These contributing factors have stymied investment in and discovery of new therapeutics to meet the emerging unmet need of treating antibiotic-resistant infections.

As a result, in 2017, we have arrived at a point where there are few treatment options for many Gram-negative infections, where methicillin-resistant *Staphylococcus aureus* is more common than susceptible strains and where infections due to *Clostridium difficile* are increasingly drug resistant and mortal. Subsequently, clinicians are being forced to resort to older, less well-tolerated drugs to treat resistant microbes. The global community is rapidly approaching the prospect of drug-resistant bacterial epidemics that will have the potential to claim millions of lives and produce an enormous financial burden on health-care systems worldwide. A second golden age of antibiotic drug discovery is desperately needed.

There have been many recommendations for addressing antibiotic resistance including new stewardship control measures, better hygiene, and new methods to identify at-risk patients. Indeed, several valuable, recent initiatives have been started by the U.S. and European governments and regulators to dramatically speed up and reduce the cost antibiotic drug development and many incentives are now available for these pursuits. However, almost everyone that has sought to address this problem agrees that the long-term solution is discovery and introduction of new antibiotic targets and new chemical matter that leads to novel therapeutics. This book presents the latest advancements to this end. The eight chapters in this book provide an exciting discussion of novel targets in purine and isoprenoid biosynthesis, lipopolysaccharide transport, and biofilm production. Also included are reviews of unique targets in tuberculosis and *Clostridium difficile* infections, narrow spectrum antibiotics, as well as a discussion of a new antibiotic isolated from soil bacteria. The chapters focus on targets

and inhibitors that are not clinically used, but represent new approaches towards the treatment of resistant infections. It is our hope that the reader will draw inspiration from this collection of scientific advancements and join the critical effort to discover and develop the next era of antibiotics. We are certain that without these new innovations, the next 75 years will not be as healthy as the last.

Steven M. Firestine and Troy Lister
Editors

Contents

Chapter 1	Treatment of <i>Clostridium difficile</i> Infections	1
	<i>Christopher Yip, Jacqueline Phan and Ernesto Abel-Santos</i>	
1.1	Background	1
1.2	CDI Symptoms and Progression	5
1.3	Relapse	5
1.4	Diagnosis	6
1.5	Prevention Measures—General Hospital Practice and Other Prevention Methods	7
1.6	Current Treatment and Antibiotics	9
1.6.1	Anti-Toxins	10
1.6.2	Vaccines	12
1.6.3	Anti-Germinants	13
1.6.4	Fecal Transplantation	13
1.6.5	Probiotics	14
1.7	Conclusion	15
	References	15
Chapter 2	Targeting Purine Biosynthesis for Antibacterial Drug Design	20
	<i>Gyan Modi, Shibin Chacko and Lizbeth Hedstrom</i>	
2.1	Introduction	20
2.1.1	The <i>De novo</i> Purine Nucleotide Biosynthesis Pathway	21
2.1.2	The Purine Conversion Pathways	22
2.1.3	The Purine Salvage Pathways	24
2.1.4	Availability of Purine Bases and Nucleosides	25

Drug Discovery Series No. 58

Antibiotic Drug Discovery: New Targets and Molecular Entities

Edited by Steven M. Firestone and Troy Lister

© The Royal Society of Chemistry 2017

Published by the Royal Society of Chemistry, www.rsc.org

2.1.5	The Complex Interplay Between Salvage Pathways and Precursor Availability	25
2.2	The Essentiality of Enzymes of the Purine Biosynthetic Pathways	26
2.2.1	Essentiality of Purine Nucleotide Biosynthesis for Growth in Rich Media	26
2.2.2	Essentiality of Purine Nucleotide Biosynthesis During Infection	27
2.2.3	Inhibitors May Not Have the Same Phenotypes as Gene Knockouts	30
2.2.4	The Problem of Resistance	30
2.3	Progress Targeting the Enzymes of <i>De novo</i> Purine Nucleotide Biosynthesis	30
2.4	Progress Targeting Enzymes in the Purine Nucleotide Conversion Pathways	31
2.4.1	IMPDH Structure and Mechanism	32
2.4.2	Prokaryotic and Eukaryotic IMPDHs: A Comparative Analysis of Rational Drug Design	34
2.4.3	Repurposing <i>Cryptosporidium</i> IMPDH Inhibitors as Antibiotics	36
2.5	Conclusion	38
	Acknowledgements	38
	References	39
Chapter 3	Inhibitors of Biofilm Production	43
	<i>Roberta J. Melander and Christian Melander</i>	
3.1	Introduction	43
3.2	Biofilms	43
3.3	Strategies for Combating Biofilms	44
3.3.1	Quorum Sensing Inhibitors	44
3.3.2	Inhibitors of AHL Based Quorum Sensing as Biofilm Inhibitors	45
3.3.3	Inhibitors of AIP-Based Quorum Sensing as Biofilm Inhibitors	47
3.3.4	Inhibitors of AI-2 Based Quorum Sensing as Biofilm Inhibitors	48
3.4	Inhibition of Bacterial Signaling Pathways	49
3.4.1	Interference with c-di-GMP Signaling to Inhibit Biofilm Formation	49
3.4.2	Inhibition of Indole Signaling Pathways to Prevent Biofilm Formation	50
3.4.3	Inhibition of Two-Component Signal Transduction Systems (TCS) to Prevent Biofilm Formation	52
3.4.4	Inhibition of Other Signaling Pathways to Prevent Biofilm Formation	53

3.5 Identification of Natural Products and Analogues that Prevent Biofilm Formation	54
3.5.1 Plant Natural Products and Analogues that Prevent Biofilm Formation	54
3.5.2 Marine Natural Products and Analogues that Prevent Biofilm Formation	55
3.5.3 Other Natural Products that Prevent Biofilm Formation	58
3.6 Antimicrobial Peptides (AMPs) that Prevent Biofilm Formation	58
3.7 Inhibition of Efflux to Prevent Biofilm Formation	60
3.8 Matrix Degradation to Prevent Biofilm Formation	60
3.9 Conclusions	62
References	62
Chapter 4 Narrow Spectrum Antibacterial Agents	76
<i>Lauren A. Spagnuolo, Peter J. Tonge and Stewart L. Fisher</i>	
4.1 Introduction	76
4.2 Natural Products	80
4.3 Synthetic and Target-Based Approaches	86
4.4 Future Prospects	93
4.5 Conclusions	95
References	95
Chapter 5 The LPS Transport Pathway: A New Target for the Development of Gram-Negative Antibiotics	103
<i>Alison M. Berezuk and Cezar M. Khursigara</i>	
5.1 Introduction	103
5.2 Lipopolysaccharide (LPS) and the Gram-Negative Cell Envelope	105
5.3 The LPS Biosynthesis Pathway	106
5.3.1 Kdo ₂ -Lipid A	106
5.3.2 Core Polysaccharide	109
5.3.3 O-Antigen	111
5.4 LPS Modification and Its Role in Gram-Negative Bacterial Persistence	111
5.5 LPS Transport: The Lpt Pathway	112
5.5.1 Extraction of LPS from the IM	112
5.5.2 Traversing the Periplasm: The LptA Protein Bridge	113
5.5.3 LPS Insertion into the OM	114
5.6 LPS Transport as a New Target for the Development of Gram-Negative Antibiotics	115
5.7 Conclusions	120
References	120

Chapter 6	The Discovery of Teixobactin	127
	<i>L. Lazarides, J. Y. C. Chiva, M. Jones and V. A. Steadman</i>	
6.1	Introduction	127
6.2	Cultivating the Unculturable – The iChip	128
6.3	Teixobactin – A Novel Antibiotic	129
6.4	Structural Determination of Teixobactin	130
6.5	Synthesis of Teixobactin and Analogues	135
6.6	Conclusion	139
	References	139
Chapter 7	Emerging Targets in Anti-Tubercular Drug Design	141
	<i>Keith D. Green, Selina Y. L. Holbrook, Huy X. Ngo and Sylvie Garneau-Tsodikova</i>	
7.1	Introduction	141
7.1.1	The Biology and Pathology of TB	145
7.1.2	Current Drug Targets	148
7.1.3	Resistance Related to TB	150
7.2	Discovery and Validation of Novel Drug Targets in TB	153
7.2.1	Targets Involved in <i>Mycobacterium tuberculosis</i> Cell Envelope Biosynthesis	153
7.2.2	Targets Involved in <i>Mycobacterium tuberculosis</i> General Metabolism	164
7.3	Synergistic Drug Combination Therapy	186
7.3.1	Unrelated Compounds	186
7.3.2	Inhibitors of Resistance Enzymes	186
7.3.3	P2X ₇ Receptor Agonist	187
7.4	Conclusion and Perspectives	188
	Acknowledgements	188
	References	188
Chapter 8	Antibacterial Leads Targeting Isoprenoid Biosynthesis	204
	<i>Carl J. Balibar</i>	
8.1	Introduction	204
8.2	Targeting the MVA Pathway	207
8.2.1	Historic Compounds Inhibiting the MVA Pathway	207
8.2.2	Screening for Inhibitors of the MVA Pathway in Bacteria	208
8.2.3	Targeting the GHMP Kinase Family Members of the MVA Pathway	209
8.3	Targeting the MEP Pathway	211
8.3.1	Historic Compounds Inhibiting the MEP Pathway	211

8.3.2 Inhibiting DXS	213
8.3.3 Inhibiting IspC	217
8.3.4 Inhibiting IspD	226
8.3.5 Inhibiting IspE	227
8.3.6 Inhibiting IspF	231
8.3.7 Inhibiting IspG and IspH	234
8.4 Alternate Targets Utilizing IPP Precursors	236
8.4.1 Inhibiting IDI	236
8.4.2 Inhibiting UppS	238
8.4.3 Inhibiting Staphyloxanthin Biosynthesis	243
8.5 Conclusions	245
References	246

Subject Index

256

Treatment of Clostridium difficile Infections

CHRISTOPHER YIP^a, JACQUELINE PHAN^a AND
ERNESTO ABEL-SANTOS^{*a}

^aDepartment of Chemistry and Biochemistry, University of Nevada, Las Vegas, 4505 Maryland Parkway, Campus Box 4003, Las Vegas, NV 89154, USA

*E-mail: ernesto.abelsantos@unlv.edu

1.1 Background

Clostridium difficile infection (CDI) is a nosocomial disease mainly correlated with antibiotic-associated diarrhea. These infections are caused by *Clostridium difficile*, an anaerobic, rod shaped, gram-positive bacterium that is normally found in the gastrointestinal tract (Figure 1.1).¹

Approximately 5% of healthy adults, and 50% of newborns are asymptomatic carriers of *C. difficile*.² *C. difficile* was originally thought to be a commensal bacterium, but due to the recent boom of antibiotic therapies and advancements, it was quickly recognized that *C. difficile* is the leading cause of hospital-acquired diarrhea worldwide.³ In the United States alone, there are roughly 500 000 cases of CDI annually, with associated costs estimated to be approximately \$4.8 billion.⁴

C. difficile has a unique lifecycle such that it can form metabolically dormant, non-reproductive spores when stressed (Figure 1.2).⁵